Rasooli Iraj, Abdolhamidi Raziyeh, Jahangiri Abolfazl, Darvish Alipour Astaneh Shakiba
Department of Biology, Shahed University, Tehran, Iran.
Molecular Microbiology Research Center, Shahed University, Tehran, Iran.
Int J Pept Res Ther. 2020;26(4):2653-2660. doi: 10.1007/s10989-020-10056-0. Epub 2020 Mar 9.
is one of the most problematic pathogens in clinical settings. Emerging of its antibiotic-resistant strains persuade researchers to find alternative treatment options such as immunization against the notorious nosocomial pathogen. Oma87 has been introduced as an immunogenic outer membrane protein via reverse vaccinology. However, protectivity of Oma87 is not well known. The current research undertakes a study on the immunogenicity of recombinant Oma87 in a murine model. Some physico-chemical properties were assessed via in silico analyses. The corresponding gene was amplified and cloned into pET28a plasmid. The recombinant protein was purified and then was administered to immunize mice. Sera obtained from the immunized mice were assessed with respect to the triggered antibodies. Challenges were performed on actively or passively immunized mice. In silico analyses revealed that this protein is the same as BamA. A high titer of specific antibody was raised against rOma87 even after the first injection. The specific antibody recognized the whole cell of . Both active and passive immunizations confer 100 and 50% protection, respectively against ~ 2 × lethal dose (LD) of in the murine sepsis model. Although none of mice received ~ 5 × LD of survived in passive immunization, 25% of mice challenged with ~ 7 × LD of the bacteria survived and the dead mice exhibited a delayed death. Based on these results, Oma87 is the same as BamA which could be considered as a promising vaccine candidate against in the sepsis model.
是临床环境中最具问题的病原体之一。其抗生素耐药菌株的出现促使研究人员寻找替代治疗方案，例如针对这种臭名昭著的医院病原体进行免疫接种。通过反向疫苗学，Oma87已被作为一种免疫原性外膜蛋白引入。然而，Oma87的保护效力尚不清楚。当前的研究在小鼠模型中对重组Oma87的免疫原性进行了研究。通过计算机分析评估了一些物理化学性质。扩增相应基因并克隆到pET28a质粒中。纯化重组蛋白，然后用于免疫小鼠。对从免疫小鼠获得的血清进行触发抗体方面的评估。对主动或被动免疫的小鼠进行攻毒。计算机分析表明该蛋白与BamA相同。即使在首次注射后，也产生了针对rOma87的高滴度特异性抗体。特异性抗体识别[病原体名称未明确]的全细胞。在小鼠败血症模型中，主动免疫和被动免疫分别对约2倍致死剂量（LD）的[病原体名称未明确]提供100%和50%的保护。尽管在被动免疫中，没有小鼠在接受约5倍LD的[病原体名称未明确]后存活，但在用约7倍LD的该细菌攻毒的小鼠中，25%存活，死亡小鼠出现延迟死亡。基于这些结果，Oma87与BamA相同，在败血症模型中可被视为一种有前景的抗[病原体名称未明确]疫苗候选物。
